Impacts of GFP-FoxP3⁺ regulatory T cells on lupus hallmarks differ by genetic background and type of GFP knock-in

References

• Herrmann M, Voll RE, Kalden JR. Etiopathogenesis of systemic lupus erythematosus. Immunol Today. 2000;21:424–426.
   PubMedGoogle Scholar
• Morel L, Mohan C, Yu Y, et al. Functional dissection of systemic lupus erythematosus using congenic mouse strains. J Immunol. 1997;158:6019–6028.
   PubMed Web of Science ®Google Scholar
• Mohan C, Alas E, Morel L, et al. Genetic dissection of SLE pathogenesis. Sle1 on murine chromosome 1 leads to a selective loss of tolerance to H2A/H2B/DNA subnucleosomes. J Clin Invest. 1998;101:1362–1372.
   PubMed Web of Science ®Google Scholar
• Chang SH, Kim TJ, Kim YJ, et al. The lupus susceptibility locus Sle1 facilitates the peripheral development and selection of anti-DNA B cells through impaired receptor editing. JI. 2014;192:5579–5585.
   Google Scholar
• Kumar KR, Li L, Yan M, et al. Regulation of B cell tolerance by the lupus susceptibility gene Ly108. Science. 2006;312:1665–1669.
   PubMed Web of Science ®Google Scholar
• Ziegler SF. FOXP3: of mice and men. Annu Rev Immunol. 2006;24:209–226.
   PubMed Web of Science ®Google Scholar
• Darce J, Rudra D, Li L, et al. An N-terminal mutation of the Foxp3 transcription factor alleviates arthritis but exacerbates diabetes. Immunity. 2012;36:731–741.
   PubMed Web of Science ®Google Scholar
• Morel L, Yu Y, Blenman KR, et al. Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain. Mamm Genome. 1996;7:335–339.
   PubMed Web of Science ®Google Scholar
• Mohan C, Morel L, Yang P, et al. Genetic dissection of lupus pathogenesis: a recipe for nephrophilic autoantibodies. J Clin Invest. 1999;103:1685–1695.
   PubMed Web of Science ®Google Scholar
• Abbate M, Zoja C, Corna D, et al. Complement-mediated dysfunction of glomerular filtration barrier accelerates progressive renal injury. JASN. 2008;19:1158–1167.
   Web of Science ®Google Scholar
• Cambier JC, Gauld SB, Merrell KT, et al. B-cell anergy: from transgenic models to naturally occurring anergic B cells? Nat Rev Immunol. 2007;7:633–643.
   PubMed Web of Science ®Google Scholar
• Wing JB, Ise W, Kurosaki T, et al. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity. 2014;41:1013–1025.
   PubMed Web of Science ®Google Scholar
• Kurts C, Panzer U, Anders HJ, et al. The immune system and kidney disease: basic concepts and clinical implications. Nat Rev Immunol. 2013;13:738–753.
   PubMed Web of Science ®Google Scholar
• Melchers F. Checkpoints that control B cell development. J Clin Invest. 2015;125:2203–2210.
   PubMed Web of Science ®Google Scholar
• Sims GP, Ettinger R, Shirota Y, et al. Identification and characterization of circulating human transitional B cells. Blood. 2005;105:4390–4398.
   PubMed Web of Science ®Google Scholar
• Yurasov S, Wardemann H, Hammersen J, et al. Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med. 2005;201:703–711.
   PubMed Web of Science ®Google Scholar
• Kinnunen T, Chamberlain N, Morbach H, et al. Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. Blood. 2013;121:1595–1603.
   PubMed Web of Science ®Google Scholar
• Leonardo SM, Josephson JA, Hartog NL, et al. Altered B cell development and anergy in the absence of Foxp3. J Immunol. 2010;185:2147–2156.
   PubMed Web of Science ®Google Scholar
• Teague BN, Pan YJ, Mudd PA, et al. Cutting edge: Transitional T3 B cells do not give rise to mature B cells, have undergone selection, and are reduced in murine lupus'. J Immunol. 2007;178:7511–7515.
   PubMed Web of Science ®Google Scholar
• Vossenkamper A, Lutalo PM, Spencer J. Translational Mini-Review Series on B cell subsets in disease. Transitional B cells in systemic lupus erythematosus and Sjogren's syndrome: clinical implications and effects of B cell-targeted therapies. Clin Exp Immunol. 2012;167:7–14.
   PubMed Web of Science ®Google Scholar
• Pollard LM, Jones JR, Wood TC. Molecular characterization of 355 mucopolysaccharidosis patients reveals 104 novel mutations. J Inherit Metab Dis. 2013;36:179–187.
   PubMed Web of Science ®Google Scholar
• Domeier PP, Chodisetti SB, Soni C, et al. IFN-gamma receptor and STAT1 signaling in B cells are central to spontaneous germinal center formation and autoimmunity. J Exp Med. 2016;213:715–732.
   PubMed Web of Science ®Google Scholar
• Nie H, Zheng Y, Li R, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-alpha in rheumatoid arthritis. Nat Med. 2013;19:322–328.
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Vignali DA, Rudensky AY, et al. The plasticity and stability of regulatory T cells. Nat Rev Immunol. 2013;13:461–467.
   PubMed Web of Science ®Google Scholar
• So JS. Roles of Endoplasmic Reticulum Stress in Immune Responses. Mol Cells. 2018;41:705–716.
   PubMed Web of Science ®Google Scholar
• Xu Y, Melo-Cardenas J, Zhang Y, et al. The E3 ligase Hrd1 stabilizes Tregs by antagonizing inflammatory cytokine-induced ER stress response. JCI Insight. 2019;4:e121887.
   PubMed Web of Science ®Google Scholar
• Hoyer BF, Moser K, Hauser AE, et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J Exp Med. 2004;199:1577–1584.
   PubMed Web of Science ®Google Scholar
• Schroeder K, Herrmann M, Winkler TH. The role of somatic hypermutation in the generation of pathogenic antibodies in SLE. Autoimmunity. 2013;46:121–127.
   PubMed Web of Science ®Google Scholar
• Barilla-Labarca ML, Toder K, Furie R. Targeting the complement system in systemic lupus erythematosus and other diseases. Clin Immunol. 2013;148:313–321.
   PubMed Web of Science ®Google Scholar
• Baqi N, Moazami S, Singh A, et al. Lupus nephritis in children: a longitudinal study of prognostic factors and therapy. J Am Soc Nephrol. 1996;7:924–929.
   PubMed Web of Science ®Google Scholar
• Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007;25:1265–1275.
   PubMed Web of Science ®Google Scholar